HRTX stock forecast
Our latest prediction for Heron Therapeutics, Inc.'s stock price was made on the Oct. 3, 2019 when the stock price was at 19.36$.
In the short term (2weeks), HRTX's stock price should outperform the market by 2.12%. During that period the price should oscillate between -7.23% and +8.85%.
In the medium term (3months), HRTX's stock price should outperform the market by 1.95%. During that period the price should oscillate between -17.04% and +24.75%.Get email alerts
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
At the moment the company generates 117M USD in revenues.
On its last earning announcement, the company reported a loss of -2.54$ per share.
The book value per share is 5.56$
Three months stock forecastOct. 3, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|